VPHM - Viropharma Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nikole Wollerstein who wrote (283)	8/29/1999 8:26:00 PM
From: scaram(o)uche	Read Replies (1) of 2557

Wrong conclusion. The data (and indeed study) do not, in any way, address the conclusion that you are trying to draw. Not saying that resistance can't develop, but, again, there's been at least one study published showing that resistant viruses are substantially reduced with respect to pathogenicity. I'm actually quite pleased with that data.... 13 of 15, 87%........ it's from an independent source, and even appears to have been sponsored by a competitor. The (blinded, randomized) clinical trials show highly significant efficacy for certain endpoints. You couldn't get that data unless plec reacted with a substantial fraction of targeted viral isolates. That data actually has "synergy" written all over it, IMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next